Compounds > 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
Page last updated: 2024-12-06

9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID64988
CHEMBL ID61733
SCHEMBL ID215611
MeSH IDM0165494

Synonyms (25)

Synonym
pmedap
2-(2,6-diaminopurin-9-yl)ethoxymethylphosphonic acid
pme-dap
gs573
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine
113852-41-8
n-(2-phosphonomethoxyethyl)-2,6-diaminopurine
phosphonic acid, ((2-(2,6-diamino-9h-purin-9-yl)ethoxy)methyl)-
9-(2-phosphonomethoxyethyl)-2,6-diaminopurine
5-(3-hydroxy-2-phosphonomethoxypropyladenine)
((2-(2,6-diamino-9h-purin-9-yl)ethoxy)methyl)phosphonic acid
CHEMBL61733
5ex1yur4dh ,
unii-5ex1yur4dh
gs 0573
phosphonic acid, p-((2-(2,6-diamino-9h-purin-9-yl)ethoxy)methyl)-
SCHEMBL215611
DTXSID50150589
DB08843
Q27261941
bdbm50472235
HY-106382
EX-A5709
CS-0025693
AKOS040756486

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" (S)-HPMPA inhibited the development of tail lesions caused by vaccinia virus if it was administered intraperitoneally or subcutaneously at a dosage as low as 5 mg/kg per day."( Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.
De Clercq, E; Holý, A; Rosenberg, I, 1989)		0.28
" We compared their toxicity and ability to inhibit tumour development in two different dosage regimes with those of their parent compound PMEDAP, as well with PMEG."( Antitumour activity of N6-substituted PMEDAP derivatives against T-cell lymphoma.
Holy, A; Mandys, V; Otová, B; Valeriánová, M; Votruba, I, )		0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (67)

Assay IDTitleYearJournalArticle
AID374194Antiviral activity against Camelpox virus CML14 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID534207Antiviral activity against Varicella zoster virus Ellen infected in HFF cells by plaque reduction assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID63925Inhibitory activity against herpes simplex virus type 1 (HSV-1) McIntyre strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID83506Inhibitory activity against cytomegalovirus (CMV) Davis strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID365171Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID374201Selectivity index, ratio of CC50 for human PHK to EC50 for Camelpox virus CML1 infected in human PHK2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID63929Inhibitory activity against herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) VMW 1837 strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID393992Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID374203Cytotoxicity against HEL299 cells assessed as minimum cytotoxic concentration required for alteration in cell morphology after 4 days by microscopy2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID63923Inhibitory activity against herpes simplex virus type 1 (HSV-1) KOS strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID534218Selectivity index, ratio of EC50 for Human herpesvirus 6B Z29 to CC50 for human MOLT-3 cells2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID83510Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) YS strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID365176Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID44139Inhibitory activity against murine sarcoma virus induced transformation of murine C3H/3T3 embryo fibroblasts1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID63933Inhibitory activity against herpes simplex virus type 2 (HSV-2) G strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID534209Antiviral activity against Human cytomegalovirus AD169 infected in HFF cells by plaque reduction assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID534212Selectivity index, ratio of EC50 for Murine cytomegalovirus Smith to CC50 for human HFF cell2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID534211Antiviral activity against Murine cytomegalovirus Smith infected in HFF cells by plaque reduction assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID534210Selectivity index, ratio of EC50 for human cytomegalovirus AD169 to CC50 for human HFF cell2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID534214Selectivity index, ratio of EC50 for Epstein-Barr virus P3HR-1 to CC50 for human daudi cell2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID534205Antiviral activity against herpes simplex virus 2 MS infected in HFF cells by plaque reduction assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID393987Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID83504Inhibitory activity against cytomegalovirus (CMV) AD 169 strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID365173Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID534199Cytotoxicity against human HFF cells2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID374193Antiviral activity against Camelpox virus CML1 infected in HEL299 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374202Selectivity index, ratio of CC50 for human PHK to EC50 for Camelpox virus CML14 infected in human PHK2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID63921Inhibition of herpes simplex virus type 1 (HSV-1) F strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID374197Selectivity index, ratio of CC50 for HEL299 cells to EC50 for Camelpox virus CML14 infected in HEL299 cells2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID365169Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID534217Antiviral activity against Human herpesvirus 6B Z29 infected in human MOLT-3 cells2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID63931Inhibitory activity against herpes simplex virus type 2 (HSV-2) 196 strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID534206Selectivity index, ratio of EC50 for herpes simplex virus type 2 MS to CC50 for human HFF cell2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID365170Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID105334Inhibitory activity of compound against human immunodeficiency virus type 1 (HIV-1) induced cytopathogenicity in MT-4 cells1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID534216Selectivity index, ratio of EC50 for Human herpesvirus 6A GS to CC50 for human HSB-2 cell2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID83514Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK-) 07/1 strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID534202Cytotoxicity against human MOLT3 cell after 4 hrs by MTS assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID220592Effective concentration for the inhibition of adenovirus2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.
AID534204Selectivity index, ratio of EC50 for herpes simplex virus type 1 E-377 to CC50 for human HFF cell2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID374195Cytotoxicity against HEL299 cells after 4 days by Z1 Coulter counting analysis2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID534198Cytotoxicity against human HFF cells after 7 days by neutral red dye method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID534203Antiviral activity against herpes simplex virus 1 E-377 infected in HFF cells by plaque reduction assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID393993Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID374199Antiviral activity against Camelpox virus CML14 infected in human PHK assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID374200Cytotoxicity against human PHK after 4 days by Z1 Coulter counting analysis2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID393964Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID63937Inhibitory activity against vaccinia virus (VV)1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID365174Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID534200Cytotoxicity against human Daudi cell after 4 hrs by MTS assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID63935Inhibitory activity against herpes simplex virus type 2 (HSV-2) Lyons strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID393991Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID374204Cytotoxicity against human PHK assessed as minimum cytotoxic concentration required for alteration in cell morphology after 4 days by microscopy2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID393990Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID83508Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) OKA strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID534213Antiviral activity against Epstein-Barr virus p3hr-1 infected in human daudi cells2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID374198Antiviral activity against Camelpox virus CML1 infected in human PHK assessed as inhibition of virus-induced cytopathic effect after 6 days by Giemsa staining2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID534215Antiviral activity against Human herpesvirus 6A GS infected in human HSB-2 cells2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID83512Inhibition of varicella zoster virus thymidine kinase (VZV TK+) YS/R strain1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.
AID534208Selectivity index, ratio of EC50 for Varicella zoster virus Ellen to CC50 for human HFF cell2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID280941Cytotoxicity against mouse L1210/0 cells after 48 hrs2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the anticancer activity of nucleoside analogues: a QSAR model approach using an internally consistent training set.
AID393988Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID365172Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
AID374196Selectivity index, ratio of CC50 for HEL299 cells to EC50 for Camelpox virus CML1 infected in HEL299 cells2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.
AID534201Cytotoxicity against human HSB2 cell after 4 hrs by MTS assay2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.
AID393989Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
4-Benzyloxy-gamma-sultone derivatives: discovery of a novel family of non-nucleoside inhibitors of human cytomegalovirus and varicella zoster virus.
AID365175Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
4"-Benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (4.35)18.7374
1990's23 (50.00)18.2507
2000's15 (32.61)29.6817
2010's6 (13.04)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.50 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other50 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		6.63906-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
phosphonoacetic acid
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.		1.9910monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
cytosine
[no description available]		4.5980aminopyrimidine;
pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.0310nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		3.2760carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
floxuridine
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.		2.0310nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
idoxuridine
[no description available]		2.0310organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		3.5620alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.0310pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		1.9910adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		1.9710antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
cytarabine
[no description available]		2.6930beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
trifluridine
Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.		2.0310nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
2-aminopurine
2-Aminopurine: A purine that is an isomer of ADENINE (6-aminopurine).. aminopurine : Any purine having at least one amino substituent.. 2-aminopurine : The parent compound of the 2-aminopurines, comprising a purine core carrying an amino substituent at the 2-position.		2.07102-aminopurines;
nucleobase analogue		antimetabolite
2'-deoxyadenosine triphosphate
2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd		2102'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		1.9710
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9810azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
fiacitabine
fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro.		1.9910
adefovir
adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.		5.492106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		4.89110phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		1.99106-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		1.9710adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
thymine arabinoside
thymine arabinoside: selectively inhibits replication of herpes simplex virus		2.0310N-glycosyl compound
edoxudin
[no description available]		2.0310pyrimidine 2'-deoxyribonucleoside
2,4-diaminopyrimidine
2,6-diaminopyrimidine: structure in first source. pyrimidine-2,4-diamine : An aminopyrimidine in which a pyrimidine nucleus is substituted with amino groups at C-2 and C-4.		2.0510aminopyrimidine
2-aminoadenosine
[no description available]		1.9710purine nucleoside
9-(s)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine
[no description available]		2.9540
9-(3-hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine
9-(3-hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine: RN refers to (S)-isomer		2.4120
n-(2-(hydroxyethoxy)methyl)-5-methyluracil
N-(2-(hydroxyethoxy)methyl)-5-methyluracil: structure given in first source		2.0310
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil
5-fluoro-1-((2-hydroxyethoxy)methyl)uracil: structure given in first source		2.0310
5-hydroxymethyl-2'-deoxyuridine
[no description available]		2.0310pyrimidine 2'-deoxyribonucleoside
msh release-inhibiting hormone
[no description available]		2.0310oligopeptide
5-hydroxy-2'-deoxyuridine
5-hydroxy-2'-deoxyuridine: a major oxidation product of 2'-deoxycytidine		2.0310
5-formyl-2'-deoxyuridine
5-formyl-2'-deoxyuridine: structure given in first source		2.0310
9-(3-fluoro-2-phosphonylmethoxypropyl)adenine
9-(3-fluoro-2-phosphonylmethoxypropyl)adenine: highly selective antiretroviral agent in vivo & vitro; structure given in first source		1.9810
cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine: prodrug for HPMPC; specific name and structure not given in first source		2.0310
5-nitro-2'-deoxyuridine
[no description available]		2.0310
5-vinyl-2'-deoxyuridine
5-vinyl-2'-deoxyuridine: structure		2.0310
5-propyl-2'-deoxyuridine
5-propyl-2'-deoxyuridine: RN given refers to parent cpd		2.0310
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		6210divalent inorganic anion;
phosphite ion
cyclic-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine
cyclic-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine: specific name and structure not given in first source		2.0310
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		2102,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
adenosine-5'-carboxaldehyde
adenosine-5'-carboxaldehyde: potent inhibitor of S-adenosyl-L-homocysteine hydrolase; structure given in first source. 5'-dehydroadenosine : A member of the class of adenosines that is 5'-dehydro derivative of adenosine.		2.0310adenosines
thapsigargin
Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.		2.0210butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
brivudine
brivudine: anti-herpes agent		2.4420
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		2.4120nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
5-ethynyl-2'-deoxyuridine
5-ethynyl-2'-deoxyuridine: structure in first source		2.0310
6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine
[no description available]		2.4220
5-cyano-2'-deoxyuridine
5-cyano-2'-deoxyuridine: structure in first source		2.0310
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		1.99102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
5-(2-iodovinyl)-2'-deoxyuridine
[no description available]		2.0310
rabacfosadine
rabacfosadine: has potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma; structure in first source		3.5620
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.0510
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		3.12502-aminopurines;
oxopurine		antimetabolite;
antiviral drug
guanosine monophosphate
Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase.		210guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite
guanine
[no description available]		5.191502-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ganciclovir
[no description available]		3.11502-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
9-((2-phosphonylmethoxy)ethyl)guanine
9-((2-phosphonylmethoxy)ethyl)guanine: structure given in first source		5.31170phosphoethanolamine
9-(3-hydroxy-2-phosphonomethoxypropyl)guanine
9-(3-hydroxy-2-phosphonomethoxypropyl)guanine: structure given in first source; RN given refers to (+-)-isomer; RN for cpd without isomeric designation not available 3/89		2.6830
ConditionIndicatedRelationship StrengthStudiesTrials
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		08.2660
Cancer of Cervix
[description not available]		02.0810
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.0810
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		02.9610
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		02.9610
Angiogenesis, Pathologic
[description not available]		02.0510
T-Cell Lymphoma
[description not available]		02.4220
Lymphoma, T-Cell
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.		02.4220
Germinoblastoma
[description not available]		02.0310
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		02.0310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Herpes Simplex Virus Infection
[description not available]		02.420
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		02.420
African Sleeping Sickness
[description not available]		01.9810
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		01.9810
Cytomegalic Inclusion Disease
[description not available]		02.940
B Virus Infection
[description not available]		01.9810
Antibody Deficiency Syndrome
[description not available]		01.9810
Cytomegalovirus Infections
Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.		07.940
Immunologic Deficiency Syndromes
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.		01.9810
Experimental Leukemia
[description not available]		01.9810
EHS Tumor
[description not available]		02.3820
Graft-Versus-Host Disease
[description not available]		01.9910
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.		01.9910
Leukemia L 1210
[description not available]		01.9910
Granulocytic Leukemia
[description not available]		0210
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		0210
Cancer of the Uterus
[description not available]		0210
Choriocarcinoma
A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).		0210
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		0210
Uterine Neoplasms
Tumors or cancer of the UTERUS.		0210
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210
Cancer Syndromes, Hereditary
[description not available]		0210
Cell Transformation, Viral
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.		01.9710
Infections, Retroviridae
[description not available]		02.8910
Viral Diseases
[description not available]		02.8910
HIV Coinfection
[description not available]		02.8910
Retroviridae Infections
Virus diseases caused by the RETROVIRIDAE.		02.8910
Virus Diseases
A general term for diseases caused by viruses.		02.8910
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.8910
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		01.9710
Brain Disorders
[description not available]		01.9710
Vaccinia
The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.		01.9710
Brain Diseases
Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.		01.9710